WAVE Life Sciences
733 Concord Avenue
Cambridge
Massachusetts
02138
United States
Tel: 1-617-949-2900
Fax: 1-617-949-2901
Website: http://wavelifesciences.com/
Email: info@wavelifesci.com
About WAVE Life Sciences
WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW WAVE LIFE SCIENCES:
Tweets by Wave Life Sciences
158 articles about WAVE Life Sciences
-
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
4/23/2024
Wave Life Sciences Ltd. provided an update on its best-in-class small interfering RNA and RNA editing platform capabilities.
-
Wave Life Sciences to Present at Upcoming April 2024 Investor Conferences
3/27/2024
Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/6/2024
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
2/28/2024
Wave Life Sciences Ltd. will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates.
-
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
2/27/2024
Wave Life Sciences today announced its upcoming presentations at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 3-6 in Orlando, FL.
-
From ALS to depression to Huntington’s disease, many neuroscience-focused companies are anticipating key data over the next few months.
-
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
1/8/2024
Wave Life Sciences Ltd. announced key 2024 milestones across its clinical programs, growing pipeline, and leading RNA medicines platform.
-
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Wave Life Sciences Ltd. (Nasdaq: WVE) today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.
-
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
12/15/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the Phase 2 FORWARD-53 clinical trial, which is evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
-
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares - December 7, 2023
12/7/2023
Wave Life Sciences Ltd. announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share.
-
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
12/6/2023
Wave Life Sciences Ltd. (Nasdaq: WVE) today announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 as a potential treatment for alpha-1 antitrypsin deficiency (AATD).
-
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
11/22/2023
Wave Life Sciences Ltd. today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET.
-
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.
-
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
11/3/2023
Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 9, 2023, to review the company’s third quarter 2023 financial results and provide business updates.
-
Its reversible nature offers the potential for RNA editing to go beyond rare diseases, eliciting excitement and buy-in from large pharmas like GSK and Eli Lilly.
-
Pivotal clinical trials in Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis are expected to read out this fall. Here's a closer look.
-
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
9/28/2023
Wave Life Sciences Ltd., a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, held a virtual analyst and investor R&D Day, which highlighted the company’s growth strategy for building the leading RNA medicines company.
-
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
9/25/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023.
-
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/6/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.
-
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
9/5/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the submission of its first clinical trial application (CTA) for WVE-006 in alpha-1 antitrypsin deficiency (AATD).